Shilpa Medicare shares touched a day high on 11 September, after the company secured regulatory approval for a new anti-nausea injection.

The rally followed news that the company received final approval from the Subject Expert Committee under India’s drug regulator, CDSCO, to market OERIS, an extended release ondansetron injection.

The drug is designed to prevent chemotherapy-induced nausea and vomiting. What makes this approval notable is the dosing.

OERIS delivers anti-nausea protection for up to 120 hours, or five days, from a single injection.

That means patients undergoing chemotherapy could avoid repeat doses, which the company has said could ease treatment for patients and reduce workload for hospital staff.

The approval came after a Phase III clinical trial that tested the drug’s safety and effectiveness in patients receiving moderately to highly emetogenic chemotherapy.

Shilpa Medicare now plans to roll out OERIS commercially across India, and holds patent protection for the product in the country until 2039. This development builds on a strong quarter for the company.

For the three months ended June 2026, Shilpa Medicare reported consolidated revenue of ₹466 crore, up 45% from the same period last year. Net profit more than doubled to ₹101 crore from ₹47 crore.

Growth came from multiple areas of the business. Revenue from novel products doubled year on year, the API business grew close to 15%, and domestic formulations revenue jumped 179%. European formulations revenue also rose sharply, up 84% to ₹57 crore.

Shilpa Medicare shares closed at ₹961.15 on the NSE on 11 September, up 2.26% for the day. The stock has now gained more than 200% since the start of the year.

The future of investing is here!
Tradz by EquityPandit leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!